Review Papers Claim by Claim

 Quick Explanation Copied

The 2010 FXR review by Modica, Gadaleta and Moschetta accurately maps FXR as master regulator of bile acid, lipid, and glucose homeostasis and correctly anticipated gene-/tissue-selective FXR modulators as the therapeutic endgame — a prediction vindicated by subsequent FXR drug development FXR paradigm review paper.

 Long Explanation

Review: Deciphering the Nuclear Bile Acid Receptor FXR Paradigm (Modica, Gadaleta & Moschetta, 2010)

This review synthesizes 15 years of FXR (NR1H4) biology — from its 1995 cloning as RIP14 and mis-naming after farnesol binding, through the 1999 de-orphanization when CDCA and other primary bile acids were identified as physiological ligands FXR de-orphanization history.

Strengths. The review integrates structural biology (reverse ligand orientation in the LBD, dual LXXLL docking), the four FXRα isoforms with tissue-specific expression, and the central FXR-SHP-LRH-1 and FXR-FGF15/19-FGFR4 axes governing CYP7A1/CYP8B1 repression. It candidly reports contradictions: FXR antagonism may protect in BDL cholestasis via MRP4 induction while agonism protects in ANIT/estrogen models Contradictory cholestasis evidence acknowledged, and PEPCK regulation is disputed. Crucially, it anticipated that selective intestinal FXR activation would be therapeutically superior to systemic agonism — a concept validated in later research showing intestine-restricted modulation avoids hepatic adverse effects Intestine-selective FXR antagonist validation.

Figure: The FXR feed-forward control network from the review (arrows per review text). Rendered with vis-network.

Later evidence complicating two review claims. (1) The review frames FXR activation as protective against cholestasis, but a 2020 study showed obeticholic acid worsens rodent cholestasis via an FXR/MafG/Nrf2 axis — the review did partially anticipate this by noting hepatic FXR activation can repress the adaptive MRP4 escape route OCA worsens cholestasis via MafG/Nrf2. (2) The review attributes FXR−/− spontaneous hepatocarcinoma to systemic loss; hepatocyte-specific knockout mice show no spontaneous tumors but heightened CA/DEN susceptibility, suggesting bile acid stress, not FXR loss alone, initiates liver tumors Hepatocyte-specific FXR knockout tumor data.

Blind spots. The review relies heavily on mouse knockout models and the cholecystectomy-CRC epidemiology (correlation, confounded by indication); human FAP sampling was only two patients in the underlying tumor study FXR intestinal tumor suppression study. Postprandial FGF19-Src-Y67 FXR phosphorylation, discovered later, was not foreseeable but now adds signaling control layer absent from the purely transcriptional picture FGF19-Src-FXR phosphorylation axis.

What would change the assessment: demonstration that the FXR-FGF19 axis is not dominant for BA pool control in humans, or that gene-selective modulation cannot separate therapeutic from adverse effects.

 BGPT Paper Review

Study Novelty

A 2010 synthetic review consolidating a then-maturing field; high novelty for its era in framing tissue-/gene-selective modulation, now partially superseded.

Scientific Quality

Carefully cited (208 refs), transparently reports conflicting cholestasis and glucose data; however, some epidemiological correlations (cholecystectomy-CRC) are treated uncritically and no primary data.

Study Generality

Spans bile acid, lipid, glucose, vascular, and cancer biology — a broad metabolic framework applicable beyond FXR itself.

Study Usefulness

Directly informed FXR drug-development strategy; the selective-intestinal-FXR thesis is now embodied in current therapeutic programs.

Study Reproducibility

A review with no primary data; reproducibility rests on the cited primary studies, some with small n and mouse-only models.

Explanatory Depth

Mechanistic detail on ligand-LBD crystallography, SHP/LRH-1/FGF19 cascades, and transporter regulation, though signaling-layer (phosphorylation) biology was then unknown.